Pharvaris N.V. Files 6-K, Reports Under Form 20-F

TL;DR

Pharvaris N.V. (PHVS) filed a 6-K, confirming 20-F reporting. Standard procedure.

AI Summary

Pharvaris N.V. filed a Form 6-K on July 24, 2025, reporting as a foreign private issuer. The filing indicates that the company will file its annual reports under Form 20-F. The company's principal executive offices are located in Leiden, The Netherlands.

Why It Matters

This filing confirms Pharvaris N.V.'s reporting status and adherence to SEC regulations for foreign private issuers, providing transparency for investors.

Risk Assessment

Risk Level: low — This is a routine administrative filing confirming reporting status and not disclosing new material financial or operational information.

Key Players & Entities

• Pharvaris N.V. (company) — Filer of the 6-K report
• 001-40010 (company) — SEC File Number for Pharvaris N.V.
• 20250724 (date) — Filing date of the 6-K
• Leiden, The Netherlands (location) — Location of principal executive offices

FAQ

From the Filing

0001193125-25-164426.txt : 20250724 0001193125-25-164426.hdr.sgml : 20250724 20250724161838 ACCESSION NUMBER: 0001193125-25-164426 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 8 CONFORMED PERIOD OF REPORT: 20250724 FILED AS OF DATE: 20250724 DATE AS OF CHANGE: 20250724 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharvaris N.V. CENTRAL INDEX KEY: 0001830487 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40010 FILM NUMBER: 251147108 BUSINESS ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 BUSINESS PHONE: 31 (0)71 203 6410 MAIL ADDRESS: STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN STATE: P7 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Pharvaris, B.V. DATE OF NAME CHANGE: 20201029 6-K 1 d36725d6k.htm 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July, 2025 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F ☒ Form 20-F   ☐ Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. PHARVARIS N.V. On July 22, 2025, Pharvaris N.V. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC as representatives of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell (i) 9,562,500 ordinary shares, par value €0.12 per share (which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,312,500 ordinary shares) (the “Shares”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 500,000 ordinary shares in an underwritten offering (the “Offering”). The Offering closed on July 24, 2025. The Shares were sold in the Offering at the public offering price of $20.00 per share. The Pre-Funded Warrants were sold at a public offering price of $19.99 per Pre-Funded Warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such Pre-Funded Warrant. Each Pre-Funded Warrant is exercisable as of July 24, 2025 until fully exercised, subject to an ownership limitation rel